Artelo Biosciences Inc (ARTL)

03:34 AM

Artelo Biosciences (NASDAQ:ARTL) Receives “Buy” Rating from D. Boral Capital - Defense World

03:34 AM

Jun 06, 2025

Artelo Biosciences (ARTL) Receives Continued 'Buy' Rating from D. Boral Capital | ARTL Stock News - GuruFocus

Jun 06, 2025

Jun 05, 2025

Artelo Biosciences presents promising OA pain treatment data By Investing.com - Investing.com South Africa

Jun 05, 2025

Jun 05, 2025

Artelo Biosciences (ARTL) Highlights New FABP Inhibitor Data at British Pain Conference | ARTL Stock News - GuruFocus

Jun 05, 2025

Jun 05, 2025

Artelo Biosciences presents promising OA pain treatment data - Investing.com

Jun 05, 2025

Jun 05, 2025

Artelo’s Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study - Yahoo Finance

Jun 05, 2025

Jun 04, 2025

Artelo Biosciences (NASDAQ:ARTL) Stock Price Down 3.7% – Should You Sell? - Defense World

Jun 04, 2025

Jun 02, 2025

ARTL: Potential of Fabp Inhibitors in Treating Mood Disorders Hi - GuruFocus

Jun 02, 2025

Jun 02, 2025

Independent Study Confirms Breakthrough Potential of Artelo's Novel Anxiety DrugPhase 1 Data Coming - Stock Titan

Jun 02, 2025

May 28, 2025

Artelo Biosciences Reports Q1 2025 Financial Results - TipRanks

May 28, 2025

May 23, 2025

Artelo Biosciences Faces Nasdaq Compliance Challenge - TipRanks

May 23, 2025

May 13, 2025

ARTELO BIOSCIENCES, INC. SEC 10-Q Report - TradingView

May 13, 2025

May 13, 2025

Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results - GlobeNewswire

May 13, 2025

May 10, 2025

Artelo Biosciences (ARTL) Expected to Announce Earnings on Monday - Defense World

May 10, 2025

Apr 29, 2025

Artelo Biosciences’ (ARTL) Buy Rating Reaffirmed at D. Boral Capital - Defense World

Apr 29, 2025

Apr 29, 2025

Artelo Biosciences (ARTL) Reports Promising Psoriasis Treatment Advances | ARTL Stock News - GuruFocus

Apr 29, 2025

Apr 28, 2025

EXCLUSIVE: Artelo Biosciences' New Peer-Reviewed Research Shows Effectiveness Of Psoriasis Candidate In Animal Models - AOL.com

Apr 28, 2025

Apr 28, 2025

Artelo Biosciences Announces Publication of New Peer-Reviewed Re - GuruFocus

Apr 28, 2025

Apr 28, 2025

Artelo Biosciences Reports Positive Effects Of ART26.12 In Psoriasis Models - Nasdaq

Apr 28, 2025

Apr 28, 2025

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis | ARTL Stock News - GuruFocus

Apr 28, 2025

Apr 28, 2025

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis - The Manila Times

Apr 28, 2025

Apr 28, 2025

Artelo Biosciences Announces Positive Preclinical Results for Psoriasis Treatment ART26.12 in Journal of Investigative Dermatology - Nasdaq

Apr 28, 2025

Apr 28, 2025

Breakthrough Oral Psoriasis Treatment Matches Current Drugs in New Research, Phase 1 Results Coming - Stock Titan

Apr 28, 2025

Apr 28, 2025

Short Interest in Artelo Biosciences, Inc. (NASDAQ:ARTL) Grows By 58,220.0% - Defense World

Apr 28, 2025

Apr 24, 2025

Artelo Biosciences (NASDAQ:ARTL) Shares Down 11.2% – What’s Next? - Defense World

Apr 24, 2025

Apr 16, 2025

Third Harmonic Bio (THRD) Plans Liquidation; Significant Search Surge in Biotech Sector | ARTL Stock News - GuruFocus

Apr 16, 2025

Apr 15, 2025

Artelo Biosciences (ARTL) Advances Novel Pain Therapy with Upcoming Data - GuruFocus

Apr 15, 2025

Apr 15, 2025

Artelo Biosciences (ARTL) Advances Cancer Therapy Pipeline - GuruFocus

Apr 15, 2025

Apr 14, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Apr 14, 2025

Apr 09, 2025

ARTL stock touches 52-week low at $0.85 amid market challenges - Investing.com

Apr 09, 2025

Apr 04, 2025

D. Boral Capital Reaffirms Buy Rating for Artelo Biosciences (NASDAQ:ARTL) - Defense World

Apr 04, 2025

Mar 31, 2025

Artelo Biosciences stock hits 52-week low at $0.91 - Investing.com

Mar 31, 2025

Mar 31, 2025

Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025 - The Manila Times

Mar 31, 2025

Mar 31, 2025

New Data Reveals Artelo's FABP5 Inhibitor Could Transform Pain and Cancer Treatment - Stock Titan

Mar 31, 2025

Mar 17, 2025

Artelo Biosciences (ARTL) Projected to Post Earnings on Monday - Defense World

Mar 17, 2025

Mar 13, 2025

Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update - Defense World

Mar 13, 2025

Mar 07, 2025

HC Wainwright Has Pessimistic View of ARTL FY2025 Earnings - Defense World

Mar 07, 2025

Mar 05, 2025

Artelo Biosciences Reports 2024 Financial Results and Clinical Progress - TipRanks

Mar 05, 2025

Mar 05, 2025

Artelo Biosciences (NASDAQ:ARTL) Given Buy Rating at HC Wainwright - Defense World

Mar 05, 2025

Mar 03, 2025

Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results - The Manila Times

Mar 03, 2025

Mar 03, 2025

ARTELO BIOSCIENCES, INC. SEC 10-K Report - TradingView

Mar 03, 2025

Mar 03, 2025

Can Artelo's Three Clinical Programs Overcome Its $9.8M Annual Loss? - StockTitan

Mar 03, 2025

Mar 02, 2025

Artelo Biosciences, Inc. (NASDAQ:ARTL) Sees Significant Increase in Short Interest - Defense World

Mar 02, 2025

Mar 02, 2025

Artelo Biosciences’ (ARTL) “Buy” Rating Reiterated at D. Boral Capital - Defense World

Mar 02, 2025

Feb 28, 2025

Artelo Biosciences reports promising nonclinical CBD study - MSN

Feb 28, 2025

Feb 20, 2025

Analyzing Artelo Biosciences (NASDAQ:ARTL) & Rafael (NYSE:RFL) - Defense World

Feb 20, 2025

Feb 14, 2025

Artelo Biosciences Reports Positive ART12.11 Tablet Data Showing Improved Pharmacokinetics - Nasdaq

Feb 14, 2025

Feb 14, 2025

Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex® - GlobeNewswire

Feb 14, 2025